期刊文献+

TOP2A在结直肠癌组织中的表达和意义 被引量:2

Expression of topoisomerase II alpha in human colorectal carcinoma and its significance
下载PDF
导出
摘要 目的检测TOP2A在结直肠癌、癌旁组织及转移癌组织中的表达,初步探讨其与结直肠癌发生发展、侵袭转移关系。方法用免疫组化及荧光定量PCR方法检测结直肠癌、淋巴结转移癌及相应癌旁组织中TOP2A在蛋白及转录水平的表达情况。结果 TOP2A蛋白在淋巴结转移癌中的表达高于原发灶及相应正常癌旁组织中的表达(P<0.05),在结直肠癌组织中TOP2A的表达与癌组织的浸润程度、淋巴结转移密切相关(P<0.05),癌组织与相应的癌旁组织相比差异则无显著性(P>0.05),其表达与癌组织分化程度也无显著性(P>0.05),在mRNA水平的检测也得到了与上述结果基本一致的结论。结论 TOP2A的表达与结直肠癌侵袭转移关系较密切,其表达水平在一定程度上提示结直肠癌的转移潜能,检测TOP2A蛋白可作为结直肠癌诊断、治疗及预后判断过程中的一种较有价值的病理学指标。 Objective To detect the correlation between the expression of topoisomerase 2 alpha (TOP2A) and the biological behaviors of human colorectal carcinoma. Methods Immunohistochemistry and real-time RT-PCR were used to detect the expression of TOP2A in colorectal carcinomas and normal mucosa. Results The protein and mRNA expressions of TOP2A in the metastatic lymph nodes were significantly higher than those in matched primary lesions and normal tissues (P〈0.05). No significant difference was found in TOP2A expressions between normal mucosa and colorectal carcinomas. The protein and mRNA expressions of TOP2A were significantly correlated to the lymph node metastasis and invasion depth (P〈0.05), but not to the differentiation of the tumor (P〉0.05). Conclusion TOP2A plays an important role in the invasion and metastasis of the colorectal carcinomas, and may serve as a valuable indicator for the diagnosis, treatment and the prognostic evaluation of the malignancy.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第8期1959-1961,1964,共4页 Journal of Southern Medical University
基金 佛山市科技攻关项目(200908119)
关键词 结直肠癌 TOP2A 免疫组织化学 荧光定量PCR colorectal carcinoma topoisomerase 2 alpha immunohistochemistry fluorescent quantitative PCR
  • 相关文献

参考文献13

  • 1Champoux JJ. DNA topoisomerascs: structure, function, and mechanism[ J ]. Annu Rev Biochem, 2001, 70: 369-3.
  • 2Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs [ J ]. Annu Rev Pharmacol Toxicol, 2001, 41: 53-77.
  • 3Wikman H, Kettunen E, Seppanen JK, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array [ J ]. Oncogene, 2002, 21: 5804-13.
  • 4Guerin E, Entz-Werle N, Eyer D, et al. Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia [J]. Leukemia, 2003, 17: 532-40.
  • 5Simon R, Atefy R, Wagner U, et aI.HER-2 and TOP2A coamplification in urinary bladder cancer[J]. Int J Cancer, 2003, 107: 764-72.
  • 6Park K, Han S, Gwak GH, et al. Topoisomerase Ⅱ-alpha gene deletion is not frequent as its amplification in breast cancer [J]. Breast Cancer Res Treat, 2006, 98: 337-42.
  • 7Liu JM, Chen LT, Li AF, et al. Prognostic implications of the expression of erbB2, topoisomerase Ⅱ alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy [J]. Jpn J Clin Oncol, 2004, 34: 727-32.
  • 8Parker LP, Taylor DD, Kesterson S, et al. Gene expression profiling in response to estradiol and genistein in ovarian cancer cells [J]. Cancer Genomics Protcomics, 2009, 6: 189-94.
  • 9Akagi T, Ito T, Kato M, et al. Chromosomal abnormalities and novel discase-relatexi regions in progression from Batrett's esophagus to csophageal adenocarcinoma [ J ]. Int J Cancer, 2009, 125: 2349-59.
  • 10Campiglio M, Somenzi G, Olgiati C, et al. Role of proliferation in HER2 status predicted response to doxorubicin [ J ]. Int J Cancer, 2003, 105: 568-73.

同被引文献24

  • 1梁智勇,王文泽,高洁,武莎斐,曾瑄,刘彤华.胰腺导管腺癌中HER2/neu和拓扑异构酶Ⅱα基因的变化及相关性分析[J].中华病理学杂志,2007,36(2):102-106. 被引量:6
  • 2吴建兵,王汉姣,王顺金,李凌,冯龙.雷替曲塞联合L-OHP与5-Fu/LV联合L-OHP方案治疗晚期结直肠癌的临床疗效比较[J].肿瘤防治研究,2007,34(9):711-713. 被引量:14
  • 3Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer inci- dence and mortality in Europe in 2006 [ J]. Ann Oncol, 2007,18 (3) :581-592.
  • 4Zaczek A, Markiewicz A, Jakiewicz J, et al. Clinical evaluation ofdeveloped PCR-based method with hydrolysis probes for TOP2ct copy number evaluation in breast cancer samples [ J ]. Clin Biochem, 2010,43( 10-11 ) :891-898.
  • 5Nakagawa M, Bando Y, Nagao T, et al. Expression of p53, Ki- 67, E-eadherin, N-eadherin and TOP2ct in triple-negative breast cancer[J]. Antieaneer Res, 2011,31 (6) :2389-2393.
  • 6Ronkainen H, Hirvikoski P, Kauppila S, et al. Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcino- ma[ J ]. J Exp Clin Cancer Res,2011,30 ( 19 ) :84.
  • 7Sapetto-Rebow B, Mc Loughlin SC, O'Shea LC, et al. Maternal topoisomerase H alpha, not topoisomerase II beta, enables embry- onic development of zebrafish TOP2c-/-mutants [ J]. BMC Dev Bi- ol, 2011,23(11) :71.
  • 8Panousis D, Patsouris E, Lagoudianakis E, et al. The value of TOP2et, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors[ J]. Eur J Gynaecol Oneol, 2011,32 (2) : 156-159.
  • 9Nielsen KV, Ejlertsen B, MoUer S, et al. The value of TOP 2A gene copy number variation as a biomarker in breast cancer: Up- date of DBCG trial 89D[J] . Acta Oncol, 2008,47(4) :725-734.
  • 10Konecny GE, Pauletti G, Untch M, et al. Association between HER 2, TOP2c, and response to anthracycline based preoperative chemotherapy in high risk primary breast cancer[ J] . Breast Canc- er Res Treat, 2010,120 ( 2 ) :481-489.

引证文献2

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部